Seretide is indicated in the regular treatment of asthma where use of a combination product (long-acting-beta2-agonist and inhaled corticosteroid) is appropriate:
– Patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting-beta2-agonist or
– Patients already adequately controlled on both inhaled corticosteroids and longacting-beta2-agonist
Note: Seretide 25/50 mcg strength is not appropriate in adults with severe asthma.
Dosage and Administration
Seretide Evohaler is for oral inhalation only.
Patients should be made aware that Seretide Evohaler must be used regularly for optimum benefit, even when asymptomatic. Patients should be regularly reassessed by a doctor, so that the strength of Seretide they are receiving remains optimal and is only changed on medical advice. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained.
Patients should be given the strength of Seretide containing the appropriate fluticasone propionate dosage for the severity of their disease